FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189242018> ?p ?o ?g. }

• W3189242018 endingPage "535" @default.
• W3189242018 startingPage "528" @default.
• W3189242018 abstract "Radionuclide molecular imaging of human epidermal growth factor type 2 (HER2) expression may enable a non-invasive discrimination between HER2-positive and HER2-negative breast cancers for stratification of patients for HER2-targeted treatments. DARPin G3 is a small (molecular weigh 14 kDa) scaffold protein with picomolar affinity to HER2. The aim of this first-in-human study was to evaluate the safety, biodistribution and dosimetry of ^99mTc-(HE)₃-G3. <b>Methods:</b> Three cohorts of patients with primary breast cancer (each including at least 4 patients with HER2-negative and 5 patients with HER2-positive tumors) were injected with either 1000, 2000 or 3000 µg of ^99mTc-(HE)₃-G3 (287±170 MBq). Whole-body planar imaging followed by SPECT was performed at 2, 4, 6 and 24 h after injection. Vital signs and possible side effects were monitored during imaging and up to 7 days after injection. <b>Results:</b> All injections were well tolerated. No side effects were observed. The results of blood and urine analyses did not differ before and after studies. ^99mTc-(HE)₃-G3 cleared rapidly from the blood. The highest uptake was detected in the kidneys and liver followed by the lungs, breasts and small intestinal content. The hepatic uptake after injecting with 2000 or 3000 µg was significantly (p<0.05) lower than the uptake after injecting with 1000 µg. Effective doses did not differ significantly between cohorts (average 0.011± 0.004 mSv/MBq). Tumor-to-contralateral site ratios for HER-positive tumors were significantly (p< 0.05) higher than for HER2-negative at 2 and 4 h after injection. <b>Conclusion:</b> Imaging of HER2 expression using ^99mTc-(HE)₃-G3 is safe, well-tolerated and provides a low absorbed dose burden on patients. This imaging enables discerning HER2-positive and HER2-negative breast cancer. Phase I study data justifies further clinical development of ^99mTc-(HE)₃-G3." @default.
• W3189242018 created "2021-08-16" @default.
• W3189242018 creator A5001315014 @default.
• W3189242018 creator A5002404985 @default.
• W3189242018 creator A5008070853 @default.
• W3189242018 creator A5011698763 @default.
• W3189242018 creator A5011722950 @default.
• W3189242018 creator A5014071440 @default.
• W3189242018 creator A5031750428 @default.
• W3189242018 creator A5036926482 @default.
• W3189242018 creator A5058335791 @default.
• W3189242018 creator A5067404822 @default.
• W3189242018 creator A5080347903 @default.
• W3189242018 creator A5082324470 @default.
• W3189242018 creator A5088872401 @default.
• W3189242018 date "2021-08-12" @default.
• W3189242018 modified "2023-10-15" @default.
• W3189242018 title "Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer" @default.
• W3189242018 cites W2115813710 @default.
• W3189242018 cites W2136802861 @default.
• W3189242018 cites W2154568434 @default.
• W3189242018 cites W2165238581 @default.
• W3189242018 cites W2171070913 @default.
• W3189242018 cites W2190644725 @default.
• W3189242018 cites W2198899045 @default.
• W3189242018 cites W2259270597 @default.
• W3189242018 cites W2267591082 @default.
• W3189242018 cites W2285875128 @default.
• W3189242018 cites W2560406314 @default.
• W3189242018 cites W2618756196 @default.
• W3189242018 cites W2791476909 @default.
• W3189242018 cites W2806209829 @default.
• W3189242018 cites W2954328971 @default.
• W3189242018 cites W2999754980 @default.
• W3189242018 cites W3005982665 @default.
• W3189242018 cites W3037832279 @default.
• W3189242018 cites W3050283202 @default.
• W3189242018 cites W3121365664 @default.
• W3189242018 doi "https://doi.org/10.2967/jnumed.121.262542" @default.
• W3189242018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34385343" @default.
• W3189242018 hasPublicationYear "2021" @default.
• W3189242018 type Work @default.
• W3189242018 sameAs 3189242018 @default.
• W3189242018 citedByCount "23" @default.
• W3189242018 countsByYear W31892420182021 @default.
• W3189242018 countsByYear W31892420182022 @default.
• W3189242018 countsByYear W31892420182023 @default.
• W3189242018 crossrefType "journal-article" @default.
• W3189242018 hasAuthorship W3189242018A5001315014 @default.
• W3189242018 hasAuthorship W3189242018A5002404985 @default.
• W3189242018 hasAuthorship W3189242018A5008070853 @default.
• W3189242018 hasAuthorship W3189242018A5011698763 @default.
• W3189242018 hasAuthorship W3189242018A5011722950 @default.
• W3189242018 hasAuthorship W3189242018A5014071440 @default.
• W3189242018 hasAuthorship W3189242018A5031750428 @default.
• W3189242018 hasAuthorship W3189242018A5036926482 @default.
• W3189242018 hasAuthorship W3189242018A5058335791 @default.
• W3189242018 hasAuthorship W3189242018A5067404822 @default.
• W3189242018 hasAuthorship W3189242018A5080347903 @default.
• W3189242018 hasAuthorship W3189242018A5082324470 @default.
• W3189242018 hasAuthorship W3189242018A5088872401 @default.
• W3189242018 hasBestOaLocation W31892420181 @default.
• W3189242018 hasConcept C121608353 @default.
• W3189242018 hasConcept C126322002 @default.
• W3189242018 hasConcept C126894567 @default.
• W3189242018 hasConcept C138944611 @default.
• W3189242018 hasConcept C185592680 @default.
• W3189242018 hasConcept C202751555 @default.
• W3189242018 hasConcept C2777807558 @default.
• W3189242018 hasConcept C2989005 @default.
• W3189242018 hasConcept C522557706 @default.
• W3189242018 hasConcept C530470458 @default.
• W3189242018 hasConcept C55493867 @default.
• W3189242018 hasConcept C71924100 @default.
• W3189242018 hasConcept C75088862 @default.
• W3189242018 hasConceptScore W3189242018C121608353 @default.
• W3189242018 hasConceptScore W3189242018C126322002 @default.
• W3189242018 hasConceptScore W3189242018C126894567 @default.
• W3189242018 hasConceptScore W3189242018C138944611 @default.
• W3189242018 hasConceptScore W3189242018C185592680 @default.
• W3189242018 hasConceptScore W3189242018C202751555 @default.
• W3189242018 hasConceptScore W3189242018C2777807558 @default.
• W3189242018 hasConceptScore W3189242018C2989005 @default.
• W3189242018 hasConceptScore W3189242018C522557706 @default.
• W3189242018 hasConceptScore W3189242018C530470458 @default.
• W3189242018 hasConceptScore W3189242018C55493867 @default.
• W3189242018 hasConceptScore W3189242018C71924100 @default.
• W3189242018 hasConceptScore W3189242018C75088862 @default.
• W3189242018 hasIssue "4" @default.
• W3189242018 hasLocation W31892420181 @default.
• W3189242018 hasLocation W31892420182 @default.
• W3189242018 hasLocation W31892420183 @default.
• W3189242018 hasOpenAccess W3189242018 @default.
• W3189242018 hasPrimaryLocation W31892420181 @default.
• W3189242018 hasRelatedWork W1815039196 @default.
• W3189242018 hasRelatedWork W1987262526 @default.
• W3189242018 hasRelatedWork W2334983041 @default.
• W3189242018 hasRelatedWork W2346524871 @default.

• next